Powered by World Leading Researchers
Streamlining Downstream Bioprocessing
Our process reduces the cost of downstream bioprocessing by reducing the number of steps for faster purification and higher yield.
Reduced Cost
Simplified Approach
Faster Purification
Reduced Number of Steps
Higher Yield
A More Effective Process
Longer Shelf Life
High Bioavailability and Stability
About Us
Producing Any Protein As a Stable and Pure Crystal
From Loughborough University’s World Leading Research Group
BioCrystal Tech is a world leading research group at Loughborough University working on cells acting as mini-factories to produce target biopharmaceuticals and purify them by forming crystals inside living cells.
Our protein crystals have high bioavailability and stability for longer shelf life, and our in cellulo crystallisation process streamlines the chromatography process downstream, saving time and improving product recovery and yield. This technology will increase reliability of protein manufacture and reduce the loss of batches during GMP scale up, saving time and money.
High Bioavailability and Stability
Streamlined Chromatography Process
Improved Product Recovery and Yield
Cost and Time Efficient GMP Scale Up
Our Technology
Increasing The Application of Proteins Globally
Our process streamlines downstream bioprocessing by minimizing steps, enhancing purification speed and boosting protein yield.
By reducing the number of downstream purification steps, our innovative system accelerates manufacturing saving both time and money. Our innovative system can be used to produce any protein as a stable and pure crystal.
This not only saves time but also improves product recovery and yield without the use of expensive buffers or environmentally harmful solvents. Such technology enhances the reliability of protein manufacturing and minimizes batch losses during GMP scale-up.
Bringing New Drugs To Market
Our techonology aims to meet the global demand to bring new medicines to market to treat diseases that have no cure, replace medicines with adverse side effects and reduce treatment costs.
Eliminating Traditional Manufacturing Risks
Traditional manufacturing methods carry the risk of protein aggregation and denaturation during GMP scale up which is highly disruptive and costly. Our system minimises these risks by producing any protein as a stable and pure crystal.
Meeting Global Demand
Traditional manufacturing and scale up pipelines struggle to match global market demands for novel medicines. Our innovative new simplified system streamlines downstream bioprocessing to meet a much larger demand.
Help Us Develop The Right Technologies For
Bringing Medicines To Market
Our Team
John Stuart Turner
Entrepreneurial Lead
Dr. Huaiyu Yang
Principle Scientific Advisor
Dr. Monalie Bandulasena
Technology Transfer Representative
Dr. Nick Pope
Business Advisor
Get In Touch
Email us at:
J.Turner10@lboro.ac.uk